Immunotherapy Motolimod Fails to Improve Survival in Ovarian Cancer
The addition of the immune therapy motolimod to pegylated liposomal doxorubicin failed to improve overall survival among women with recurrent epithelial ovarian carcinoma in a randomized phase II trial.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers News Ovarian Cancer Conferences/SGO 2017 Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Conferences | Epithelial Cancer | Immunotherapy | Ovarian Cancer | Ovaries | Women